Kisho

SEAGEN INC. — Rare Disease Pipeline | Kisho | Kisho

SEAGEN INC.

Other

Orphan Designations

FDA Approvals

Rare Diseases

News Articles

Disease	Drug(s)	Designation	Approved
HER2 positive breast carcinoma	Tukysa	Orphan Designation	-
Her2-receptor negative breast cancer	Tukysa	Orphan Designation	-
Hodgkins lymphoma	Adcetris	Orphan Designation	-
adult neuronal ceroid lipofuscinosis	tucatinibAdcetris	Orphan Designation	-
adult pleomorphic rhabdomyosarcoma	tucatinibAdcetris	Orphan Designation	-
adult-onset non-insulinoma persistent hyperinsulinemic hypoglycemia	TukysatucatinibAdcetris	Orphan Designation	-
adult-onset proximal spinal muscular atrophy, autosomal dominant	tucatinibAdcetris	Orphan Designation	-
breast cancer	tucatinib	Orphan Designation	-
cervical cancer	TIVDAK	-	FDA Approved
congenital heart disease	Adcetris	Orphan Designation	-
congenital lethal erythroderma	Adcetris	Orphan Designation	-
esophageal cancer	humanized immunoglobulin G1 anti-integrin beta-6 monoclonal antibody conjugated to monomethyl auristatin E	Orphan Designation	-
gastric cancer	disitamab vedotin	Orphan Designation	-
hormone receptor-positive breast cancer	Tukysa	Orphan Designation	-
malignant carotid body paraganglioma	Adcetris	Orphan Designation	-
mature T-cell and NK-cell non-Hodgkin lymphoma	Adcetris	Orphan Designation	-
metachromatic leukodystrophy, adult form	Adcetris	Orphan Designation	-
mycosis fungoides	Adcetris	Orphan Designation	-
plasma cell myeloma	Nonfucosylated humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting B-cell maturation antigen (SEA-BCMA)	Orphan Designation	-
post 5-alpha-reductase inhibitors treatment syndrome	Adcetris	Orphan Designation	-
post-treatment Lyme disease syndrome	Adcetris	Orphan Designation	-
primary adult heart tumor	TukysatucatinibAdcetris	Orphan Designation	-
primary cutaneous CD30+ T-cell lymphoproliferative disease	Adcetris	Orphan Designation	-
primary cutaneous T-cell non-Hodgkin lymphoma	Brentuximab vedotin	Orphan Designation	-
primary cutaneous anaplastic large cell lymphoma	Adcetris	Orphan Designation	-
primary cutaneous follicle center lymphoma	Adcetris	Orphan Designation	-
primary cutaneous lymphoma	Adcetris	Orphan Designation	-
treatment-refractory schizophrenia	Adcetris	Orphan Designation	-
triple-positive breast carcinoma	Tukysa	Orphan Designation	-

← Back to Companies